CollPlant, Israel-based maker of regenerative tissue, files for $25M IPO

CollPlant, an Israel-based biotech focused on regenerative medicine for tissue repair, is looking to raise $25 million in an initial public offering, according to an SEC filing.

CollPlant markets wound care and orthopedics scaffolds that are based upon its virgin collagen, Collage, which is derived from plants. It offers the first plant-derived source of Type I recombinant human collagen, according to the company.

In the regulatory filing, the company said it plans to list on the Nasdaq under the symbol “CLGN.” The sole bookrunner for the offering was listed as Ladenburg Thalmann & Co. No pricing terms were outlined in the filing.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

“We believe the market opportunity for our current product candidates utilizing our rhCollagen platform technology exceeds $5 billion,” the company said.

Its VergenixSTR, which was granted at CE Mark last week, is an orthobiologic used to treat indications within the soft tissue repair market. According to CollPlant, more than 4.4 million procedures are carried out for the treatment of tendinopathy each year in the U.S. alone, which would give the company a target market for VergenixSTR of about 3 million procedures per year, or about a $2 billion market.

The company went public on the Tel Aviv Stock Exchange in 2010 through a reverse merger.

Read more on

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.